Search results for "Monoclonal Antibody"

showing 10 items of 356 documents

Common antigenic determinant on ductular cells of normal pancreas, on mucosal cells of the gastrointestinal tract and on CEA

1990

CEA is widely used as a human tumour marker and was first defined by Gold and Freedman in 1965 as an antigenic component in cancers derived from gastrointestinal tract epithelium. It is a member of a large family of immunologically related glycoproteins that vary in size and tissue distribution. Studies with c-DNA clones for CEA and NCA reveal that this family consist only of a limited number of different proteins with variable glycosylation, due to post-transcriptional modifications. The complete gene family includes about 10 closely related genes. Recently it was published that in contrast to mRNA coding for CEA, mRNA coding for NCA was expressed predominantly in cancerous tissues. A mono…

chemistry.chemical_classificationmedicine.medical_specialtyGastrointestinal tractmedicine.drug_classBiologyMonoclonal antibodyMolecular biologyEpitheliumEpitopemedicine.anatomical_structureEndocrinologychemistryAntigenInternal medicinemedicineGene familyGlycoproteinGene
researchProduct

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences

2022

Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies treatment, designed to provide superior efficacy and specific targeting of tumor cells, compared to systemic cytotoxic chemotherapy. Their structure combines highly potent anti-cancer drugs (payloads or warheads) and monoclonal antibodies (Abs), specific for a tumor-associated antigen, via a chemical linker. Because the sensitive targeting capabilities of monoclonal Abs allow the direct delivery of cytotoxic payloads to tumor cells, these agents leave healthy cells unharmed, reducing toxicity. Different ADCs have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (…

cytotoxic payloadlinkersmonoclonal antibodylymphomaAntibody-drug conjugate
researchProduct

Towards Translational ImmunoPET/MR Imaging of Invasive Pulmonary Aspergillosis: The Humanised Monoclonal Antibody JF5 Detects Aspergillus Lung Infect…

2017

Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease of hematological malignancy or bone marrow transplant patients caused by the ubiquitous environmental fungus Aspergillus fumigatus. Current diagnostic tests for the disease lack sensitivity as well as specificity, and culture of the fungus from invasive lung biopsy, considered the gold standard for IPA detection, is slow and often not possible in critically ill patients. In a previous study, we reported the development of a novel non-invasive procedure for IPA diagnosis based on antibody-guided positron emission tomography and magnetic resonance imaging (immunoPET/MRI) using a [64Cu] DOTA-labeled mouse monoclonal anti…

dota0301 basic medicinePathologyMonoclonal AntibodyMedizininflammatory diseasesMedicine (miscellaneous)ImmunoPET/MRI.AcetatesAspergillosisEpitopeAspergillus fumigatusMicepet/mriCricetinaeMedicine[ SDV.IB ] Life Sciences [q-bio]/BioengineeringPharmacology Toxicology and Pharmaceutics (miscellaneous)biologyMagnetic Resonance Imaging3. Good healthInfectious DiseasesAspergillus/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being[SDV.IB]Life Sciences [q-bio]/BioengineeringFemaleAntibodyrevealsResearch Papermedicine.medical_specialtymedicine.drug_class030106 microbiologyLung biopsyCHO CellsMonoclonal antibodyAntibodies Monoclonal HumanizedAspergillus nidulans03 medical and health sciencesHeterocyclic Compounds 1-RingCricetulusSDG 3 - Good Health and Well-beingAntigenIn vivo[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologygalactofuranoseAspergillosisAnimalsImmunoPET/MRIAntibodies FungalInfectious Diseases; Aspergillus; Aspergillosis; Monoclonal Antibody; JF5; ImmunoPET/MRIbusiness.industryfumigatusmedicine.diseasebiology.organism_classificationMice Inbred C57BLCopper RadioisotopesJF5Positron-Emission Tomographybiology.proteinbiosynthesisRadiopharmaceuticalsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyTheranostics
researchProduct

Interleukin-1β (IL-1β) Is a Modulator of Human Luteal Cell Steroidogenesis: Localization of the IL Type I System in the Corpus Luteum1

1999

The present investigation examined the effect of interleukin-1beta (IL-1beta) on progesterone production by human luteal cells and the expression and localization of the IL-1 system in the human corpus luteum (CL). Luteal cells were isolated from corpora lutea collected throughout the luteal phase. After dispersion, luteal cells were treated with a panel of monoclonal antibodies directed to leukocyte-specific molecules. The leukocytes were isolated with immunomagnetic beads. Leukocyte-free luteal cells exhibited greater steroidogenic responsiveness to hCG toward the end of the luteal phase. The treatment of mixed luteal cells (total luteal cells) with IL-1beta inhibited by 60% hCG-stimulate…

endocrine systemmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryLuteal phaseMonoclonal antibodyBiochemistryEndocrinologyImmune systemInternal medicinemedicineReceptorreproductive and urinary physiologybiologyurogenital systemBiochemistry (medical)medicine.anatomical_structureEndocrinologyCytokineCell culturebiology.proteinAntibodyCorpus luteumhormones hormone substitutes and hormone antagonistsThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Classification of current anticancer immunotherapies.

2014

© 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

immunostimulatory cytokinesmedicine.medical_treatmentReviewBioinformaticsDNA-based vaccinesEfficacy0302 clinical medicineCancer immunotherapyNeoplasmspeptide-based vaccines0303 health sciencesPatología//purl.org/becyt/ford/3.1 [https]CANCER3. Good healthMedicina BásicaOncologycheckpoint blockers030220 oncology & carcinogenesisQR180//purl.org/becyt/ford/3 [https]ImmunotherapyCIENCIAS MÉDICAS Y DE LA SALUDmedicine.drug_classInmunologíaadoptive cell transfer; checkpoint blockers; dendritic cell-based interventions; DNA-based vaccines; immunostimulatory cytokines; peptide-based vaccines; oncolytic viruses; Toll-like receptor agonistsMonoclonal antibodydendritic cell-based interventionsToll-like receptor agonistsRC025403 medical and health sciencesImmune systemAntigen[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologyadoptive cell transfer030304 developmental biologyIMMUNOTHERAPIESbusiness.industryCancerImmunotherapymedicine.diseaseR1Oncolytic virusoncolytic virusesImmunologybusinessOncotarget
researchProduct

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

2018

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to improve with the incorporation of this new class of agents with current MM therapies. However, both antigens are also expressed on other normal tissues including hematopoietic lineages and immune effector cells, which may limit their long-term clinical use. B cell maturation antigen (BCMA), a transmembrane glycoprotein in the tumor necrosis factor receptor superfamily 17 (TNFRSF17), is expressed a…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.drug_classT-Lymphocytesmedicine.medical_treatmentImmunologyReceptors Antigen T-CellT-Cell Antigen Receptor Specificitymonoclonal antibody drug conjugateReviewAntibodies Monoclonal HumanizedMonoclonal antibodyImmunotherapy Adoptivebi-specific antibody03 medical and health sciences0302 clinical medicineAntigenSignaling Lymphocytic Activation Molecule FamilyAntibodies BispecificmedicineAnimalsHumansImmunology and AllergyElotuzumabbusiness.industrySLAMF7B-Cell Maturation AntigenAntibodies MonoclonalImmunotherapychimeric antigen receptor T cellADP-ribosyl Cyclase 1Chimeric antigen receptormultiple myelomaB-cell maturation antigen030104 developmental biologymonoclonal antibody030220 oncology & carcinogenesisProteasome inhibitorCancer researchImmunotherapytargeted immunotherapylcsh:RC581-607businessmedicine.drugFrontiers in Immunology
researchProduct

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab

2015

International audience; Natalizumab (NTZ), a monoclonal antibody recognizing the alpha4 integrin chain, has been approved for the treatment of active multiple sclerosis, but expose to the onset of a rare side effect, progressive multifocal leukoencephalopathy (PML). Estimating the individual risk of PML in NTZ-treated patients is a major challenge, and therapeutic strategies are mainly guided by the overall PML risk assessed by identified risk factors: JC virus (JCV) seropositivity, treatment duration (with peak incidence after 24 months), and the previous use of immunosuppressive therapies. Given that this stratification does not yet allow a precise individual prediction of PML, other pred…

lcsh:Immunologic diseases. Allergy[SDV.IMM] Life Sciences [q-bio]/ImmunologySide effectmedicine.drug_classvirusesImmunologyJC virusReview Articlerisk stratificationCD11aJC virusmultiple sclerosismedicine.disease_causeMonoclonal antibodyCD49dprogressive multifocal leukoencephalopathyNatalizumabeffector memory T-cellst effector memory cellsImmunology and AllergyMedicineselectinPMLbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyvirus diseasesmedicine.disease3. Good healthJCVImmunologySelectins[SDV.IMM]Life Sciences [q-bio]/Immunologylcsh:RC581-607businessmedicine.drugFrontiers in Immunology
researchProduct

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies

2018

Daratumumab has proven to be highly efficacious for relapsed and refractory multiple myeloma (MM) and has recently been approved in the frontline setting for MM patients ineligible for transplantation. In the future, expanded indications are possible for daratumumab and other anti-CD38 monoclonal antibodies in development. For several years, it has been recognized that these therapies interfere with blood bank testing by binding to CD38 on red blood cells and causing panagglutination on the Indirect Antiglobulin Test. This can lead to redundant testing and significant delays in patient care. Given the anticipated increase in utilization of anti-CD38 monoclonal antibodies, as well as the tra…

lcsh:Immunologic diseases. Allergymedicine.medical_specialtyErythrocytesBlood transfusionmedicine.drug_classmedicine.medical_treatmentImmunologyAntineoplastic AgentsReview030204 cardiovascular system & hematologyCD38Monoclonal antibody03 medical and health sciences0302 clinical medicinemedicineHumansImmunology and AllergyBlood TransfusionDiagnostic ErrorsIntensive care medicinetransfusionIsatuximabbusiness.industryAntibodies MonoclonalDaratumumabdaratumumabADP-ribosyl Cyclase 1TransplantationCoombs TestBlood Grouping and Crossmatchingmonoclonal antibodyPractice Guidelines as TopicIndirect Antiglobulin Testlcsh:RC581-607Multiple MyelomabusinessCD38Blood bankProtein Bindingisatuximab030215 immunologyFrontiers in Immunology
researchProduct

The affinities of monoclonal antibodies against core antigen of hepatitis B virus

1994

Four monoclonal antibodies generated against the recombinant core antigen of hepatitis B virus are investigated for antigen binding. All exhibit a similar affinity to polystyrene-sorbed antigen but only one of them interacts with native form of HBcAg (an assembled particle) in solution. The presence of 0.1% sodium dodecylsulphate is required for the binding of other three antibodies. The phenomenon can be interpreted as inaccessibility of the corresponding epitopes unless the multimeric antigen structure is disrupted. The core antigen coated on polystyrene is considered as a similar exposed structure.

medicine.drug_classAntibody AffinityBiologyAntibodies Viralmedicine.disease_causeMonoclonal antibodyEpitopeEpitopesMiceAntigenVirologymedicineAnimalsHepatitis B virusHybridomasT-cell receptorAntibodies MonoclonalSodium Dodecyl SulfateGeneral Medicinebiology.organism_classificationHepatitis B Core AntigensVirologyMolecular biologyRecombinant ProteinsHBcAgHepadnaviridaebiology.proteinAntibodyArchives of Virology
researchProduct

Monoclonal antibody 3H8: A useful tool in the diagnosis of candidiasis

1999

In a previous series of experiments six mAbs were obtained against cell wall extracts of Candida albicans ATCC 26555. After several studies only one of them, designated 3H8, has been used to produce a commercial kit for the rapid diagnosis of candidiasis, Bichro-latex albicans (Fomouze Diagnostics). The present study involved the generation and characterization of this mAb as an immunoglobulin G1 which recognizes mannoproteins of high molecular mass present in the C. albicans cell wall. ELISA assays showed that the presence of the epitope recognized by mAb 3H8 was similar in both yeast and mycelial cell walls of C. albicans, in contrast to the epitope for mAb 1B12, which is mainly expressed…

medicine.drug_classBiologyMonoclonal antibodyMicrobiologyEpitopeMicrobiologyCell wallEpitopesAntibody SpecificityCell WallmedicineHumansCandida albicansAntibodies Fungalchemistry.chemical_classificationCandidiasisAntibodies Monoclonalbiology.organism_classificationImmunohistochemistryYeastCorpus albicanschemistrybiology.proteinReagent Kits DiagnosticAntibodyGlycoprotein
researchProduct